Skip to content

Citius Oncology, Inc. CTOR Financing Cash Flow

Financing Cash Flow at other companies

Merck & Co. logo
Merck & Co.MRK
-$2.98B+48.2%
Delcath Systems logo
Delcath SystemsDCTH
-$2.38M-173%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$94.34M-34.2%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$380K
Immunome logo
ImmunomeIMNM
-$135K-100%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$3M-97.9%

Other financials

Income statement

See full
Revenue$1.7M
Gross profit$1.3M
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Citius Oncology, Inc.’s 10-Q, filed February 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s financing cash flow?
Citius Oncology, Inc. (CTOR) reported financing cash flow of $15.13M in Q4 2025.
How has Citius Oncology, Inc.'s financing cash flow changed year-over-year?
Citius Oncology, Inc.'s financing cash flow increased by 298.9% year-over-year, from $3.79M to $15.13M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.